Adenine News and Research

RSS

Adenine is one of the four bases in DNA that make up the letters ATGC, adenine is the "A". The others are guanine, cytosine, and thymine. Adenine always pairs with thymine.

Novel DNA sensing pathway linked to increased susceptibility to malaria

Scientists at the University of Massachusetts Medical School have uncovered a novel DNA-sensing pathway important to the triggering of an innate immune response for malaria. Activation of this pathway appears to stimulate production of an overabundance of type-1 interferon by the immune system that may contribute to inflammation and fever in malaria patients and could play a part in susceptibility for the most common and lethal form of malaria known as plasmodium falciparum.

5 Aug 2011

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of ORENCIA (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis.

30 Jul 2011

Scientists discover new bases of DNA

For decades, scientists have known that DNA consists of four basic units -- adenine, guanine, thymine and cytosine. Those four bases have been taught in science textbooks and have formed the basis of the growing knowledge regarding how genes code for life.

22 Jul 2011

Cornell grants ChromaDex worldwide rights to novel manufacturing process for nicotinamide riboside

ChromaDex Corp. today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).

14 Jul 2011

Scientists pioneer way to find more chromosomal aberrations in tumors

Washington University Pediatric Cancer Genome Project scientists pioneer way to find more chromosomal aberrations in tumors; results likely to advance understanding of cancer.

13 Jun 2011

NIST's new reference can aid in Huntington's disease diagnosis

A new Standard Reference Material from the National Institute of Standards and Technology will help clinical genetics labs accurately diagnose Huntington's disease, an inherited degenerative brain disorder that usually begins between ages 35 and 50 and progressively leads to physical impairment, dementia and death.

15 Apr 2011

Scientists develop new approach to accelerate evolution of biomolecules in lab

Scientists at Harvard University have harnessed the prowess of fast-replicating bacterial viruses, also known as phages, to accelerate the evolution of biomolecules in the laboratory.

11 Apr 2011

Mitochondrial defect inherited from mother is linked to high blood pressure in one Chinese family

A specific genetic defect in one Chinese family shows that high blood pressure was inherited from the female parent, researchers report in Circulation Research: Journal of the American Heart Association.

1 Apr 2011

New technique may find 'hidden' receptors in nerve cells

Scientists at The Scripps Research Institute and University of Pennsylvania have found a way to uncover potential drug targets that have so far remained hidden from researchers' view.

11 Mar 2011

Novel labeling technique helps researchers to explore DNA chemical modification

Researchers at Emory University School of Medicine and the University of Chicago have developed a method for labeling and mapping a "sixth nucleotide," whose biological role scientists are only beginning to explore.

14 Dec 2010

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.

7 Dec 2010

EHNA treatment blocks spontaneous differentiation of stem cells

Human embryonic stem cells have enormous potential for use in pharmaceutical development and therapeutics; however, to realize this potential there is a requirement for simple and reproducible cell culture methods that provide adequate numbers of cells of suitable quality.

26 Nov 2010

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany.

18 Nov 2010

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.

8 Nov 2010

Researchers unveil mechanism of candida infections

More than half of all people are hosts to Candida albicans in their bodies. This species might be located on their skin or mucous membranes or in the intestines frequently without causing any symptoms. However, it can be dangerous to patients whose immunological system has been weakened such as after organ transplants or chemotherapy with cancer. Then, this fungus penetrates into deeper layers of tissue and uses the blood system to spread throughout the body. In Germany alone, several thousand people die from systemic candida infections every year.

29 Sep 2010

Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.

20 Sep 2010

Myrexis to present poster on cancer metabolism inhibitor program

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.

17 Sep 2010

Fralin Life Science Institute professor receives grant from NSF to elucidate research on fungi

Pablo Sobrado, assistant professor of biochemistry with the Fralin Life Science Institute at Virginia Tech, has received a $1.1 million grant from the National Science Foundation (NSF) to advance his research on the mechanism of iron acquisition in fungi and mycobacteria.

19 Aug 2010

New DNA sequencing method can lead to effective individualized medicine

In experiments with potentially broad health care implications, a research team led by a University of Washington physicist has devised a method that works at a very small scale to sequence DNA quickly and relatively inexpensively.That could open the door for more effective individualized medicine, for example providing blueprints of genetic predispositions for specific conditions and diseases such as cancer, diabetes or addiction.

17 Aug 2010

Genetics research team discovers new recurrent translocations

A genetics research team based at The Children's Hospital of Philadelphia continues to discover recurrent translocations—places in which two chromosomes exchange pieces of themselves. As many as 1 in 600 persons carry balanced chromosome translocations, which involve no loss or gain of DNA. Most such people appear healthy, but may have a child with abnormal chromosome composition and disabilities resulting from disrupted, extra or missing copies of genes.

30 Jul 2010